



09/522705-17/\$

FEE TRANSMITTAL for FY 2001 (Small Entity)		Complete if Known	
		Application Number	09/522,705
		Filing Date	April 19, 2000
		First Named Inventor	Shiuan CHEN et al.
		Examiner Name	C. Fronda
		Group Art Unit	1652
Total Amount of Payment	(\$ 55.00)	Attorney Docket Number	2124-311

RECEIVED
TECH CENTER 1600/2900
DEC 06 2002

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge additional fees and credit any overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Manbeck
- ☒ Charge any Additional Fee Required Under 37 CFR 1.16 and 1.17
- ☒ Applicant claims small entity status.
2. ☒ Payment Enclosed:
- ☒ Check
- ☐ Credit Card

FEE CALCULATION

1. FILING FEE

Fee Code	Fee \$	Fee Description	Fee Paid
201	370	Utility filing fee	[]
206	165	Design Filing Fee	[]
207	255	Plant Filing Fee	[]
208	370	Reissue Filing Fee	[]
214	80	Provisional Filing Fee	[]

SUBTOTAL \$

2. CLAIMS

	Extra Claims	Fee	Fee Paid
Total Claims [] - 20** = [] x \$ 9 = []			
Independent Claims [] - 3** = [] x 42 = []			
Multiple Dependent Claims + 140 = []			

**or number previously paid, if greater,

SUBTOTAL \$

12/03/2002 M6EBREM1 00000066 09522705

01 FC:2251

55.00 0P

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Code	Fee Paid	Fee Description	Fee Paid
205	65	Surcharge - late filing fee or oath	[]
227	25	Surcharge - late provisional filing fee or cover sheet	[]
139	130	Non-English specification	[]
147	2,520	For filing a request for reexamination	[]
112	920	Requesting publication of SIR prior to Examiner action	[]
113	1,840*	Requesting publication of SIR after Examiner action	[]
215	55	Extension for reply within first month	[55.00]
216	200	Extension for reply within second month	[]
217	460	Extension for reply within third month	[]
218	720	Extension for reply within fourth month	[]
228	980	Extension for reply within fifth month	[]
219	160	Notice of Appeal	[]
220	160	Filing a brief in support of an appeal	[]
221	150	Request for Oral Hearing	[]
138	1,510	Petition to institute a public use proceeding	[]
240	55	Petition to revive -unavoidable	[]
241	640	Petition to revive - unintentional	[]
242	640	Utility issue fee (or reissue)	[]
243	230	Design issue fee	[]
244	310	Plant issue fee	[]
122	130	Petitions to the Commissioner	[]
123	50	Processing fee under 37 CFR 1.17(q)	[]
126	180	Submission of Information Disclosure Statement	[]
581	40	Recording each patent assignment per property (times number of properties)	[]
246	370	Filing a submission after final rejection (37 CFR .129(a))	[]
249	370	For each additional invention to be examined (37 CFR 1.129(b))	[]
279	370	Request for Continued Examination (RCE)	[]
169	900	Request for expedited examination of a design application	[]
195	300	Publication fee for early, voluntary, or normal publication	[]
196	300	Publication fee for republication	[]
089	200	Filing an application for patent term adjustment	[]
090	400	Request for reinstatement of term reduced	[]
Other fee (specify)			[]

* Reduced by Basic Filing Fee Paid

SUBTOTAL

\$55.00

SUBMITTED BY		Complete (if applicable)	
NAME AND REG. NUMBER	Martha Cassidy, Reg. No. 44,066		
SIGNATURE		DATE	December 2, 2002
		DEPOSIT ACCOUNT USER ID	



TECH CENTER 1600/2900

#16/8
RECEIVED
DEC 06 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	Application Number	09/552,705
	Filing Date	19 April 2000
	First Named Inventor	Shiuan CHEN et al.
	Group Art Unit	1652
	Examiner Name	C. Fronda
	Attorney Docket Number	2124-311
Title of the Invention: DRUG SCREENING USING A PROLINE-RICH NUCLEAR RECEPTOR CO-REGULATORY PROTEIN/NUCLEAR RECEPTOR CO-EXPRESSION SYSTEM		

RESPONSE AFTER FINAL

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the final Office Action dated July 30, 2002, Applicants request that the Examiner reconsider the application in view of the following amendments and remarks.

IN THE CLAIMS:

Please cancel claims 44-51 and 53-55, all the pending claims, and insert new claims 56-85.

21 56. (New) A screening method for identifying a pair of molecules that interact with a nuclear receptor co-regulatory peptidic molecule that contains a binding sequence of SEQ ID NO:5 via said binding sequence, wherein said pair of molecules consists of a polypeptide first molecule comprising a nuclear hormone receptor peptide and a second molecule, the method comprising:

- a. providing a cell culture;
- b. cotransfecting said cell culture with a library of nucleic acids that encode said first molecules to be screened, a nucleic acid that encodes said nuclear